BCL2 and diffuse large B-cell lymphoma: To further validate our in vitro finding that SRF231 effectively targets venetoclax resistant cells, we utilized BH3 profiling to study primary samples from patients with CLL and DLBCL to identify those that had reduced BCL-2 dependence (Fig. 6A).